One Dose, Years of Relief? What Psilocybin Trials Found in People With Cancer
Before psilocybin was tested for everyday depression, researchers tested it on people with life-threatening cancer. The results from Johns Hopkins, NYU and a community cancer practice in Maryland are some of the most durable in the field. Here's what each trial found, the caveats that come with them, and why a patient in Canada can get it legally while one in the U.S. mostly can't.
How Long Does Relief Last? Antidepressants vs. Psychedelics, by the Numbers
A new Lancet Psychiatry analysis of 115 trials found Lexapro, Cymbalta and agomelatine do best at keeping depression away over months of daily use. Psychedelic drugs promise something different, lasting relief from one or two doses. We put the durability data side by side.
Everyone Knows Which Pill They Got. The FDA Just Said What To Do About It.
Functional unblinding is the methodological problem at the centre of psychedelic research. The FDA's final trial guidance says how sponsors must handle it — updated with a new systematic review and a more aggressive multidrug blinding proposal from UCSF, Stanford, and UC San Diego.
EMDR: The Therapy Sandra Bullock Calls 'The Most Healing' — and Prince Harry Did on Camera
Search interest in EMDR is up roughly 22% in a year, and celebrities from Sandra Bullock to Prince Harry have spoken publicly about using it. We looked at what 26 clinical trials and several recent meta-analyses actually found — and why a handful of clinicians think pairing it with psychedelics could be the next real development.
Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
We pulled three years of CEO cash and equity comp for all 10 public psychedelic companies straight from SEC proxy statements, SEDAR+ circulars, and ASX filings, then checked it against how each stock actually performed. The scatter plot shows almost no correlation at all.
How Clinical Trials Actually Work — and What It Means for the Psychedelic Industry
What does "Phase 3" actually require — how many patients, what counts as a win, who pays for it? We broke down how FDA trials really work, why psychedelics need a different rulebook than a normal pill trial, and where 5-MeO-DMT, psilocybin, LSD, and ibogaine each stand right now.
Eli Lilly Just Paid $3.8 Billion for the Same Molecule People Get From a Toad
Eli Lilly's acquisition of AtaiBeckley centers on a synthetic version of 5-MeO-DMT — the compound underground "Bufo" ceremonies harvest from a wild toad. What the deal signals for the toad, the field, and the science.
The Clinical Revolution: Psilocybin and 5-MeO-DMT Move from Underground to Evidence-Based Medicine
Rigorous clinical trials are providing what decades of anecdotal evidence couldn't: peer-reviewed data showing these compounds may offer rapid, sustained relief.